Treatment Information

Back

Prostate Cancer treatment details. Chemotherapy.

Rudolfstiftung, Vienna, Austria.

Survival: monthsCountry:Austria
Toxiciy Grade:4City/State/Province:Vienna
Treatments:ChemotherapyHospital:Rudolfstiftung
Drugs:Journal:Link
Date:Jan 2004

Description:

Patients: This Phase II study involved a total of 90 patients with hormone refractory prostate cancer. Patients were divided into two groups of 45 patients each: Group 1 and Group 2.

Treatment: For patients in Group 2 the treatment consisted of the chemotherapy drug estramustine (emcyt).

Toxicity: Grade 3-4 toxicities included: cardiovascular, diarrhea, nausea, vomiting, neurological, bilirubin rise, and hematologic.

Results: Median survival was 50.9 weeks (11.7 months).

Correspondence: W. Albrecht, MD




Back